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Abstract
Objective: To assess the clinical effect of medication monitoring using the West Wales Adverse Drug Reaction (ADR) Profile
for Respiratory Medicine.
Design: Single-site parallel-arm pragmatic trial using stratified randomisation.
Setting: Nurse-led respiratory outpatient clinic in general hospital in South Wales.
Participants: 54 patients with chronic respiratory disease receiving bronchodilators, corticosteroids or leukotriene receptor
antagonists.
Intervention: Following initial observation of usual nursing care, we allocated participants at random to receive at follow
up: either the West Wales ADR Profile for Respiratory Medicine in addition to usual care (‘intervention arm’ with 26
participants); or usual care alone (‘control arm’ with 28 participants).
Main Outcome Measures: Problems reported and actions taken.
Results: We followed up all randomised participants, and analysed data in accordance with treatment allocated. The
increase in numbers of problems per participant identified at follow up was significantly higher in the intervention arm,
where the median increase was 20.5 [inter-quartile range (IQR) 13–26], while that in the control arm was 21 [23 to +2]
[Mann-Whitney U test: z = 6.28, p,0.001]. The increase in numbers of actions per participant taken at follow up was also
significantly higher in the intervention arm, where the median increase was 2.5 [1–4] while that in the control arm was 0 [2
1.75 to +1] [Mann-Whitney U test: z = 4.40, p,0.001].
Conclusion: When added to usual nursing care, the West Wales ADR Profile identified more problems and prompted more
nursing actions. Our ADR Profile warrants further investigation as a strategy to optimise medication management.
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Introduction
Iatrogenic harm is a persistent concern [1]. No pharmacological
therapy that is effective is free of adverse effects [2]. Adverse drug
reactions (ADRs), defined as any untoward and unintended
response in a patient or investigational subject to a medicinal
product that relates to any dose administered [3], range from
minor and reversible through disability to death. Preventable
ADRs account for 3.7% of hospital admissions in developed
countries [4], and generate a 4.7% mortality rate in hospital [5].
Five per cent of inpatients experience ADRs [6], rising to 14% in
elderly care wards [7]. Thus, this issue causes international
concern. In the UK, about 6.5% of hospital admissions are due to
ADRs, most of which are preventable [8,9]; however we know less
about the prevalence of ADRs in the community not associated
with hospital admission [10].
ADRs are an important source of patient harm and healthcare
expenditure. However there is significant heterogeneity between
studies in risk of bias, populations, settings and methods used to
identify ADRs [8,11–13]. In the US, ADRs are recognised in the
top six causes of death [14], costing $370 per ADR case for
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emergency department visits [15]. The cost of each ADR case is
estimated at J2250 in Germany [16]. In the UK, ADR-related
admissions alone cost the NHS an estimated £466 m per annum
[10]; however, this estimate does not account for non-hospital
contact [17]. Variability in identifying, recording and reporting of
adverse events and ADRs accentuates this public health problem.
Improved monitoring of, and response to, identified ADRs is an
international priority to reduce the unnecessary burden of
treatment, yet remains under-researched [18–22].
Background
There are underlying weaknesses in current medication
management practice internationally, particularly medication
monitoring for known ADRs of prescribed drugs [18,20,21,23–
25]. Healthcare systems have traditionally relied on patient and
clinician self-reports, prescription-event monitoring and case-
control studies. These approaches capture serious and unexpected
ADRs, whilst minor to moderate ADRs are typically less well
reported [26] but remain burdensome to service users. Despite the
advantages of service user ADR reporting [27], under-reporting is
widely recognised: in a clinical trial only 1.5–5.1% (5/328-11/216)
of ADR-related problems were spontaneously reported to
physicians, increasing to 29–49% (96/328-105/216) when a
questionnaire on specific known ADRs was administered [28],
and the overall ADR reporting rate may be around 1% [29]. A
survey of 661 outpatients in Boston identified that 37% of
ameliorable ADRs were related to failure of service users to inform
physicians (19/51) [30]. Public awareness of ADR reporting
remains low [31,32]: a survey of 2028 UK adults indicated that
while 477 (24%) had experienced an ADR, only 172/2028 (9%)
were aware of reporting mechanisms [33,34]. ADR reporting by
physicians may retain an element of subjectivity [35,36], and the
long-term effects of educational interventions to increase ADR
reporting are unclear [37]. Further investment is needed to
develop feasible evidence-based strategies, that engage service
users [32], and are not overly time consuming, and explore their
clinical impact [18,19,20,23,24,38–43].
Respiratory Medicine
Thirty five million Americans live with chronic lung disease
[44], and the financial burden of lung disease in Europe is
estimated at J100 billion, of which, J6.7 billion is prescription
drug costs [45]. In the UK, almost 8 million individuals suffer with
lung disease, accounting for 7% of all drugs prescribed [46].
Inhaled beta-agonists, often prescribed in tandem with corticoste-
roids, are among the top ten drugs causing ADRs [47]. However,
no comprehensive and validated medication monitoring profile in
respiratory medicine has been located. Guidelines on the
management of chronic respiratory diseases are available
[48,49], but do not describe medication monitoring.
To address this deficit, the West Wales ADR (WWADR) Profile
for respiratory medicine has been developed from existing
literature summarising adverse effects [50–53], and tested for
cognitive form, validity and reliability [22,54]. This paper sets the
foundation for larger trials of nurse-led medication monitoring
initiatives.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information, see Checklist S1 and
Protocol S1.
Ethics Statement
Favourable ethical opinion for this study was received from the
South West Wales Research Ethics Committee (February 2010
reference 09/WMW02/60). This allowed the study to take place
in the National Health Service (NHS) in South West Wales. The
University, as trial sponsors, accepted this decision, and did not
seek further review. Patient information sheets were available in
English and Welsh ahead of gaining informed written consent
from all participants. All participant data were anonymised.
Aim
We aimed to explore the clinical effect of nurse-led medication
monitoring using the West Wales ADR (WWADR) Profile for
Respiratory Medicines. Key outcomes were changes in problems
found and actions taken during nurse-patient consultations before
and after introduction of the ADR Profile.
Setting
A nurse-led outpatient respiratory clinic in a large 600-bed
general hospital in South West Wales, that serves an urban and
rural population of around 600,000.
Design
We undertook a single-site parallel-arm pragmatic randomised
trial with stratified random allocation performed by West Wales
Organisation for Rigorous Trials in Health (WWORTH), the local
clinical trials unit [table 1]. At observation 1, all patients received
usual outpatient care, which included checking patients’ medica-
tion, symptoms, health and wellbeing. At their next scheduled
outpatient visit, observation 2, the control arm received usual care
only, while the intervention arm, in addition to usual care,
received medication monitoring with the ADR Profile. The
researcher observed all consultations. The interval between the
first and second round of observations was dictated by the nurses’
clinical judgment, based on participants’ needs.
The Intervention
The WWADR Profile for Respiratory Medicine was used in the
intervention arm at observation two [table 1] by the respiratory
nurse specialists working in the outpatient clinic. The WWADR
Profile [54] is a five-sectioned ADR symptom questionnaire
uniting problem detection with actions over five sections
comprising 81 items (57 questions, 4 observations, 7 measure-
ments, 13 checks of laboratory data), covering symptoms of the
known ADRs of corticosteroids, bronchodilators and leukotriene
receptor antagonists. We derived these items from the literature on
ADRs [22,50–53], invited service users and expert clinicians to
scrutinise them for relevance, feasibility and accuracy, and
investigated validity and reliability [54]. Targeted questions seek
to identify problems that may be indicative of ADRs, and merit
attention regardless of aetiology. For example: muscular weakness
may be symptomatic of steroid-induced metabolic changes or
hypokalaemia [50–52,55]; reports of mood changes may indicate
steroid-induced mood disorders [56–58] or hypokalaemia [51–53].
The Profile also includes health promotion advice that is
particularly pertinent to users of respiratory medicines. For
example, high salt intake may exacerbate steroid-induced fluid
retention [52]. The risk of adverse reactions is reduced, but not
eliminated, when inhaled preparations are used [53].
Randomisation
We undertook remote randomisation after the first round of
observations. We had selected five stratification variables from the
Randomised Trial of Medication Monitoring
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literature and previous work [54]: age (more or less than median of
61 years), number of respiratory medicines (more or less than
median of two), number of other drugs prescribed (more or less
than median of five), sex and day of initial observation (Wednesday
or Friday clinic). We passed participant study numbers and
stratification variables to WWORTH by telephone. They used a
dynamic randomisation algorithm based on weighted squared-
difference measures of imbalance to allocate participants in the
ratio of 1:1 and balance the five stratification variables without
blocking [59]. We used hospital numbers to track participants’
return to clinic for the second round of observations.
Participants
Patients were screened by their consultant and nurses to ensure
they were well enough to participate. All eligible patients were
approached in respiratory outpatient clinics January 2011–
January 2012.
Inclusion Criteria:
N Established clients of the nurse-led outpatient respiratory clinic
N Existing chronic respiratory condition
N Currently prescribed at least one of: bronchodilators, cortico-
steroids or leukotriene receptor antagonists
Exclusion Criteria:
N Aged 16 or under
N Lack of fluency in English or Welsh
N Considered by their nurses or consultant to lack the capacity to
consent, or to be unduly stressed or vulnerable (for example
the recently bereaved).
Outcome Measures
Primary outcomes:
1.1. Change in numbers of problems found per participant
between observations one and two
1.2. Change in numbers of actions taken per participant between
observations one and two
Secondary outcomes:
2.1. Numbers with at least one action taken at observation two
2.2. Numbers of actions taken per participant at observation two
Data Collection and Measurement of Outcomes
Data on problems identified and actions taken were collected
for each participant at both observations using a structured
template of possible ADRs [54] [table 1]. The nurse completed an
independent copy of the WWADR Profile for the intervention
participants. In addition, the researcher kept freehand field notes,
primarily to indicate all nursing actions taken. Nurses and patients
were asked to comment on use of the Profile and identify possible
harm to patients.
For outcome 2.1, ADR actions were distinguished from all
actions: ADR actions were those directly prompted by the
WWADR Profile whilst ‘all actions’ also included those identified
from usual care, or discussion around questions in the WWADR
Profile.
Sample Size
Previously, 14/20 patients receiving usual care and 1/20
patients responding to a structured monitoring instrument had
no ADRs on a monitoring profile addressed by their nurses
[60,61]. A sample of 34, 17 in each arm, is sufficient to detect this
difference in incidence of nursing actions with 90% power when
using 1% significance level [62]. To allow for potential losses to
follow up within available resources, the sample was inflated to 54.
Blinding
At observation one, the nurse, researcher and participants were
unaware of intended allocation. However, at observation two,
participants, based on their previous experience in clinic, might
have guessed that they were receiving the intervention. Nurses
were unblinded when delivering the intervention. The researchers
were aware of allocation during observation, but were blinded for
analysis.
Data Analysis
Data were analysed using IBM SPSS statistics version 19. Data
were double entered and checked for data entry errors. No
mistakes were identified. To test whether data were normally
distributed we used the Shapiro-Wilk test for samples smaller than
50 and the Kolmogorov-Smirnov test for samples larger than 50.
To compare between arms those variables found not to be
normally distributed we used the Mann-Whitney U test, the non-
parametric equivalents of the t test. Categorical variables were
tested by chi squared tests or Fisher’s exact test and logistic
regression using the backward likelihood ratio criterion. Using
‘increased number of ADR-related actions taken at observation
two’ as the outcome variable, arm allocation, age, sex and
consultation two duration were entered into univariate models as
sole predictor variables. Arm allocation was then tested with each
of the four other variables iteratively. Participants’ comments are
included for illustration.
Results
A total of 63 eligible patients were seen in clinic, 54 were
recruited (86%). No losses occurred and all participants were
Table 1. Trial design.
Clinic visit 1 and data collection 1 Interval between clinic visits
Clinic visit 2 and data
collection 2
Intervention arm Usual care +
Observation of 26 consultations
Usual care Usual care + WWADR
Profile + Observation
of 26 consultations
Control arm Usual care + Observation
of 28 consultations
Usual care Usual care +
Observation of 28 consultations
doi:10.1371/journal.pone.0096682.t001
Randomised Trial of Medication Monitoring
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analysed in accordance with their original allocation [figure 1].
Control participants were asked to attend on Wednesdays and
intervention participants on Fridays. Although 18 participants
attended on the ‘incorrect’ day, all received the treatment
allocated.
Some interval variables were not normally distributed, neces-
sitating non-parametric testing. Table 2 shows that the trial arms,
comparable at the first consultation, differed in the length of the
second consultation.
Outcomes 1.1 & 1.2. Changes in Numbers of Problems
Found and Actions taken per Participant between
Observations One and Two
The change in numbers of problems found per participant
between observations one and two was significantly different
(intervention arm median 20.5, [inter-quartile range (IQR) 13 to
26]; control arm median 21, [IQR 23 to 2]: Mann-Whitney U
1.50, z 6.28, p,0.001) [table 3]. The change in all actions taken
was also significant (intervention arm median 2.5, [IQR 1 to 4];
control arm median 0 [21.75 to +1]: Mann-Whitney U 112.50, z
4.40, p,0.001) [table 3].
Outcome 2.1. Number of Participants with at Least One
Action taken at Observation Two
No significant difference was observed in the numbers of
participants with at least one action taken at observations one and
two [table 4]. However, the difference in ADR specific actions was
significant. At observation two, 1 of 26 (4%) intervention
participants had no ADR actions taken, compared with 9 of 28
(32%) controls: X2 5.40, df 1, p 0.02, OR 11.84 (1.38–101.70)
[table 4].
Outcome 2.2. Number of Actions taken per Participant at
Observation Two
At observation two, significantly more actions were taken in the
intervention arm (median 4, inter-quartile range 3–6) than the
control arm (median 2, inter-quartile range 1–3): Mann-Whitney
U 112.00, z 4.42, p,0.001, r 0.60 [table 5; figure 2].
Multivariate Analysis
The only significant predictor of increased number of ADR-
related actions was arm allocation.
Other predictors were not significant when tested alone or with
‘trial arm’ [Table S1]. Only one participant had a negative result
Figure 1. Flow of participants through the trial.
doi:10.1371/journal.pone.0096682.g001
Randomised Trial of Medication Monitoring
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for ‘at least one action taken at observation 2’ and ‘at least one
ADR action taken at observation 2’, precluding multivariate
analysis.
Clinical Impact
Problems identified in response to using the WWADR Profile,
along with lifestyle factors, included:
N Muscular weakness affecting activities of daily living (22/26,
84.6%), muscular pain (18/26, 69.2%).
N Dry mouth, hoarseness, problems with teeth or dentures,
changes in taste or smell of the participants’ breath (19/26,
73.1%).
N Tendency to bruising (17/26, 65.4%), delayed skin healing
(16/26, 61.5%). For example: participant 004, who regularly
took aspirin and a combined corticosteroid/bronchodilator
inhaler, reported ‘‘bruises with the slightest knock, sometimes
very bad’’ and attributed this to ‘‘just with getting older,
normal’’.
N Salt regularly added to meals or during cooking (17/26,
65.4%).
N Mood problems (16/26, 61.5%). For example, the nurse
commented: ‘‘I would not have picked up on participant 014’s
depression [without the WWADR Profile]’’.
N Fine tremor affecting activities of daily living (12/26, 46.2%).
For example: participant 023, who took a high dose of beta
agonists, was identified by the ADR Profile as having a fine
motor tremor, and commented ‘‘they [hands] shake now but I
put it down to age… …get annoyed with myself dropping
things’’.
Actions taken by the participants’ nurses in response to using the
WWADR Profile included:
N 32 referrals to other healthcare professionals. Most referrals
were to the patients’ primary care practitioners [27/32,
84.4%] for: urinary dysfunction (4); falls/balance problems
(2); mood problems (1); prescription of additional medication,
for example to treat oral candidiasis (2), suspected infection (3).
N 21 occasions where health promotion advice was given, such as
maintaining immunisation status (12), smoking cessation (5)
and diet (3).
N 19 instances of advice regarding medication concordance, for
example to order replacement inhalers from primary care in a
timely manner or change medication regimen. Examples
included commencement of gradual withdrawal of corticoste-
roids (p026) and treatment of oral candidiasis (p026).
N 12 instances where oral care advice was given: rinsing mouth
following administration of inhaled medication (7), visiting
dentist to pre-empt problems relating to xerostomia (5).
N 9 occasions where patients were advised to send a sputum
sample for culture and sensitivity before antibiotics were used.
Harms
Implementation of the WWADR Profile was neither observed
nor reported to be directly harmful. The time taken identifying
and responding to problems found may be burdensome to nurses,
however, the two nurses involved reported structuring their future
care around the Profile. No participant reported negatively on the
amount of time spent in clinic or completing the WWADR Profile.
Discussion
We believe this paper reports the first randomised trial of nurse-
led medication monitoring in respiratory medicine. We offer
preliminary evidence that formalised and concurrent nurse-led
medication monitoring increases the number of patient problems
found and responded to; however, interpretation of these findings
rests with readers. Using a structured ADR Profile alongside usual
care has potential to increase early detection of problems and may
therefore ameliorate or pre-empt ADRs and improve patients’
wellbeing and health outcomes [41,63–66]. Identification of
problems may prompt the multidisciplinary team to take
preventive actions that allow patients to remain well, in
accordance with treatment and disease management priorities
[67]. It is unlikely that confounding variables account for the
differences found, since dynamic randomisation ensured even
distribution of variables, reduced biases and maximised the
strength of findings [59,68,69], and logistic regression identified
treatment allocated as the only significant predictor of having
more ADR actions taken.
Medication Monitoring: an Orphan Task
The strength of patient safety initiatives is influenced by the
personnel using them and the organisation in which they are used
[70]. Whilst nurses, doctors, pharmacists and patients are all
eligible to report ADRs, the task of medication monitoring has not
been formally embraced by any one profession [24,60,71].
Pharmacists have played an integral role in the success of the
Finland asthma programme and medication adherence [72,73],
and may be well-placed to monitor medication and review
prescriptions [63,74,75], but obstacles to their on-going involve-
ment in medication monitoring need to be identified [76]. As
inter-professional role boundaries shift and nurses assume roles
Table 2. Participant and consultation characteristics.
Control arm (n=28, unless otherwise stated) Intervention arm (n=26)
Number male (%) 13 (46%) 13 (50%)
Mean age at observation one in years (SD) 63.71 (13.6) 62.38 (10.3)
Mean number of respiratory drugs* at observation one (SD) 2.29 (0.8) 2.12 (0.6)
Mean number of respiratory drugs* at observation two (SD) 2.36 (0.8) 2.12 (0.6)
Mean consultation one length, minutes (SD) 14.75 (9.8) 13.85 (8.6)
Mean consultation two length, minutes (SD) 9.15 (9.8) (n = 27) 19.19 (8.7)
Interval between observations 1 and 2 in weeks (SD) 18.39 (10.1) 17.85 (10.8)
*Those in the inclusion criteria plus theophylline.
doi:10.1371/journal.pone.0096682.t002
Randomised Trial of Medication Monitoring
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previously in the medical domain, such as prescribing, there is
potential to integrate ADR profiles with nurse-led care. The
WWADR Profile helps minimise variation in practice, but
organisational uptake should be supported by protected time,
learning resources, leadership, dissemination and evaluation [42].
The WWADR Profile may also help overcome some perceived
barriers to nurse-led medication monitoring such as inter-
professional communication or lack of confidence in knowledge
of pharmacology and therapeutics [41,63–65,77–80]. With this
support, nurses, as the largest group of front-line healthcare
professionals working most closely with service users, are well-
placed to play a valuable role in medication monitoring [81,82].
The Profile itself could be easily transferred across healthcare
settings and may alleviate under-reporting of drug-related
problems [83,84].
Limitations of the Study
As the lasting impact of responding to drug-related harm could
not be explored within the resources available to this trial, we
cannot ascertain the impact of the initiative on concordance with
therapy, enduring amelioration of problems found or long-term
harm from administration of the Profile. The Profile prompted
health promotion regarding sub-optimal health behaviours, such
as poor mouth care or adding salt to meals, and referrals to other
professionals. Although some problems were addressed immedi-
ately, such as changes in doses of respiratory medicines, clinical
gains from nurse-led medication monitoring in outpatient
departments depend, in part, on participants following advice to
contact other healthcare professionals [60,61]: for example to treat
suspected infections (12/26), obtain overdue vaccinations (12/26)
or investigate falls (2/26). Instigation of further treatment or over-
treatment would be at the discretion of professionals receiving the
referrals, and not directly attributable to the Profile. We were
unable to investigate the costs and benefits of referrals. The
relatively small sample size precluded detection of small
differences, but we feel that our findings indicate sufficient clinical
gain to warrant further exploration.
Potential bias in research should always be considered [85].
This study design risked contamination. Over the course of the
project, the nurses may have been sensitised to medication
monitoring using the WWADR Profile, and unknowingly deliv-
ered some aspect of the Profile to the control participants, diluting
the observed effect of structured medication monitoring [86].
However, the large effect sizes suggest that contamination was not
a major problem.
Blinding during outcome assessment in non-medicinal product
[87] or pragmatic trials may be difficult, or impossible, as in this
study [88,89]. Detection bias of outcomes was minimised, but not
removed, by a pre-arranged data collection template and the
relatively low subjectivity of outcomes [90] such as observation of
tremor and statements of advice. We acknowledge that unblinded
assessment may increase the risk of bias [91], in line with
observers’ expectations [92], suggesting the need for larger
multisite investigations. Systematic review indicates that some
3% assessments are likely to be misclassified [93], which would not
materially affect interpretation of our study. Observation 1
preceded randomisation.
This trial captures ADR profiles for patients in a single location;
accordingly, findings should be generalised cautiously [94,95].
However, the trial was undertaken in an outpatient nurse-led clinic
typical of many district general hospitals, using broad inclusion
criteria [95], and patients’ experiences of long-term use of
respiratory medicines are not widely reported elsewhere. We did
not test alternative instruments or additional appointments. The
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Hawthorne effect, and social desirability in the nurses’ and
participants’ behaviours and communications, cannot be dis-
counted. However, this would have affected both arms equally.
Although a good response rate was obtained, a further important
consideration is volunteer bias [96]. Volunteer bias could not be
directly explored in the current trial, as recruitment rate was high
(85%). Findings cannot be generalised to patients too busy or
unwilling to participate in research or those viewing their
healthcare providers less favourably. Those who took the time to
participate in this research may represent a subset of the
population who are particularly engaged with their healthcare
providers and prescribed regimens.
The literature offers no consensus on identifying and addressing
medicine-related harm and adverse events [82]. Many ADRs are
subtle and ill-defined, and may resemble pre-existing conditions or
ageing. Their aetiology is often multifactorial or uncertain [3]. It
was outside the remit of our nurse-led intervention to determine
the cause of each problem. Rather, by addressing the diverse
problems vulnerable to exacerbation by prescribed medicines
[20,50–53], the WWADR Profile works towards incremental
optimisation of patients’ health status. In view of the paucity of the
evidence base on potential adverse drug reactions [97,98], to
optimise clinical gain, we thought it more important to be
thorough and detailed when monitoring for potential medication-
related harms, and risk over-ascertainment, than to risk overlook-
ing potentially treatable problems of equivocal aetiology. This
approach addresses concerns of public bodies [39,99–101] and
participants that ‘‘at the moment not enough [is] done to follow-
up: how do you know medication’s any good if no one asks you?’’
(participant 020).
Interpretation
Patient safety might be improved by concurrent medication
monitoring using drug specific checklists [61,80,102–106]. The
WWADR Profile helped nurses structure and prioritise care, and
identify previously unsuspected problems. This way, known ADRs
may be predicted, pre-empted and addressed, to reduce the
burden on long-term medication users. To our knowledge, no
Figure 2. Bar chart of problems found and actions taken par participant at observations one and two.
doi:10.1371/journal.pone.0096682.g002
Table 5. Numbers of actions taken per participant: Outcome 2.2.
Intervention arm Median (IQR) Control arm Median (IQR)Mann-Whitney U Z Asymp Sig. (2-sided) r
Outcome 2.2. Numbers of actions taken per participant. Observation one
All actions 2 (0–3) 2 (0.25–2.75) 362.50 0.03 0.98 0.004
ADR related actions 1 (0–2.25) 2 (0–2) 324.00 0.72 0.47 0.10
Outcome 2.2. Numbers of actions taken per participant. Observation two
All actions 4 (3–6) 2 (1–3) 112.00 4.42 ,0.001 0.60
ADR related actions 4 (2–5) 1 (0–2) 84.50 4.91 ,0.001 0.67
doi:10.1371/journal.pone.0096682.t005
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previous trials have tested this approach [107]. In this trial,
recognising and alleviating symptoms of potential ADRs elicited
clinical gains. Completing the WWADR Profile as part of usual
care helped protect the time needed to monitor medication. We
acknowledge that larger, multisite trials may overturn these
findings, but these findings provide the impetus to pursue
proactive ADR monitoring research.
Further Research
This paper suggests that medication monitoring profiles support
nurse-led medication monitoring [79], improving the process of
care, focusing attention and reducing adverse events in health care
[104–107]. However, more evidence is needed on the long-term
effects of structured medication monitoring on clinical outcomes
[41], nursing vigilance, nurses’ workload, nurses’ and service users’
time, and acceptability [20,39,40,108–112]. In this small trial, the
benefits of medication monitoring for service users outweighed the
risks and larger, mulitsite trials of medication monitoring are
needed to explore long-term clinical impact. Piloting similar
initiatives in different drug groups and healthcare settings,
particularly in primary healthcare, where most chronic diseases
are currently managed, may enhance patient care.
Conclusion
Significant differences between intervention and control arms
were detected in the recruited sample, supporting our work on
antipsychotics [60,61,113]. Expanding nursing roles and patient-
focused chronic disease management [67] should be encouraged
and extended to routine adoption of medicines management
policies [114], including standardised medication monitoring
profiles [115]. Monitoring should be: accurate, simple, thorough,
target-based, capable of detecting insidious and long-term harm,
and of improving clinical outcomes [19]. This trial indicates that
under-reporting may be improved by structured and standardised
ADR profiles [99,116,117]. Although many preventable ADRs are
due to inadequate patient monitoring [118], many are also due to
failure to react to problems found [38]. Actions taken are thus an
important focus of this research to ameliorate preventable ADRs
[8 38 119–121], and further investigation of ADR Profiles as a
strategy to link problem identification with actions is warranted.
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